Here, we aimed to utilize the HCT-116 human colon carcinoma cell line (mut PIK3CA, mut KRASG13D, and MMR deficient) and HT-29 human colorectal adenocarcinoma cell line (mut PIK3CA, mut BRAFV600E, and mut TP53) as CRC preclinical models to investigate the therapeutic potential of PRO in combination with CAP. Here, TP53 is linked to colorectal carcinoma.